Endoplasmic reticulum protein 29 (ERp29) is a novel endoplasmic reticulum (ER) secretion factor that facilitates the transport of secretory proteins in the early secretory pathway. Recently, it was found to be overexpressed in several cancers; however, little is known regarding its function in breast cancer progression. In this study, we show that the expression of ERp29 was reduced with tumor progression in clinical specimens of breast cancer, and that overexpression of ERp29 resulted in G 0 /G 1 arrest and inhibited cell proliferation in MDA-MB-231 cells. Importantly, overexpression of ERp29 in MDA-MB-231 cells led to a phenotypic change and mesenchymal-epithelial transition (MET) characterized by cytoskeletal reorganization with loss of stress fibers, reduction of fibronectin (FN), reactivation of epithelial cell marker E-cadherin and loss of mesenchymal cell marker vimentin. Knockdown of ERp29 by shRNA in MCF-7 cells reduced E-cadherin, but increased vimentin expression. Furthermore, ERp29 overexpression in MDA-MB-231 and SKBr3 cells decreased cell migration/invasion and reduced cell transformation, whereas silencing of ERp29 in MCF-7 cells enhanced cell aggressive behavior. Significantly, expression of ERp29 in MDA-MB-231 cells suppressed tumor formation in nude mice by repressing the cell proliferative index (Ki-67 positivity). Transcriptional profiling analysis showed that ERp29 acts as a central regulator by upregulating a group of genes with tumor suppressive function, for example, E-cadherin (CDH1), cyclin-dependent kinase inhibitor (CDKN2B) and spleen tyrosine kinase (SYK), and by downregulating a group of genes that regulate cell proliferation (eg, FN, epidermal growth factor receptor (EGFR) and plasminogen activator receptor (uPAR)). It is noteworthy that ERp29 significantly attenuated the overall ERK cascade, whereas the ratio of p-ERK1 to p-ERK2 was highly increased. Taken together, our results showed that ERp29 is a novel regulator leading to cell growth arrest and cell transition from a proliferative to a quiescent state, and reprogramming molecular portraits to suppress the tumor growth of MDA-MB-231 breast cancer cells. KEYWORDS: cell cycle arrest; endoplasmic reticulum protein 29; E-cadherin; epithelial-mesenchymal transition; tumor suppressor Breast cancer recurrence is often found in patients after removal of the primary tumor and adjuvant therapy. For example, about 30-74% of breast cancer patients diagnosed at M0 or M1 tumor-node-metastasis tumor stages were found to have cancer cells in their bone marrow 1 and 20-45% of patients relapsed years or decades later.
Breast cancer recurrence is often found in patients after removal of the primary tumor and adjuvant therapy. For example, about 30-74% of breast cancer patients diagnosed at M0 or M1 tumor-node-metastasis tumor stages were found to have cancer cells in their bone marrow 1 and 20-45% of patients relapsed years or decades later. 2 Recent evidence suggests that tumor cells might disseminate at an early stage of tumor progression and evolve toward an aggressive phenotype in parallel with primary tumor. 3 Most of the disseminated cells are growth arrested at the G 0 /G 1 phase and are characterized as quiescent dormant cells with high resistance to conventional chemotherapy. 4, 5 However, the mechanisms that drive proliferative tumor cells to a quiescent state and activate survival signals in dormant cells are not fully understood.
Tumor cell dormancy is driven by complicated mechanisms, including downregulation of u-plasminogen activator receptor (uPAR), 6 loss of b1 integrin 7 or inhibition of focal adhesion kinase (FAK), 8 and upregulation of p38 signaling. 9 The uPAR/a5b1 integrin complex is essential for propagating mitogenic signals through the Ras/extracellular signalregulated kinase (ERK) pathway by recruiting FAK and the EGF receptor (EGFR). 6 Disruption of the uPAR complex activates p38 mitogen-activated protein kinase (MAPK) signaling, which may exert tumor suppression functions on metastatic cells by causing cell growth arrest, senescence or apoptosis. 10 One of the mechanisms of p38-induced dormancy involves downregulation of JUN and inhibition of eukaryotic initiation factor-2a (eIF2a) activity. 11 In addition, endoplasmic reticulum (ER) stress signaling has a key role in tumor cell dormancy by way of activating RNA-dependent protein kinase-like ER kinase/phospho-eIF2a (PERK/ p-eIF2a) signaling and inducing G 0 /G 1 arrest. [12] [13] [14] These effects have been evidenced by the fact that the PERK pathway inhibits hyperproliferation of tumor cells and tumor formation. 15 Endoplasmic reticulum protein 29 (ERp29), a novel reticuloplasmin, was first cloned from rat liver and enamel cells. 16, 17 Structurally, it has an ER-retrieval signal of the Cterminal tetrapeptide (KEEL) targeting the ER lumen, but lacks the classical chaperone, disulfide-editing, calcium-buffer, and stress-response properties. 18 It has been shown that ERp29 is directly associated with the folding and/or secretion of thyroglobulin, 19 as well as resistance to oxidative and radiation stress. 20, 21 Importantly, it was found to be highly expressed in primary tumor and cell lines. [22] [23] [24] Recent findings that ERp29 expression correlated with tumor growth rate 24 and knockdown of ERp29 by siRNA in noninvasive MCF-7 breast cancer cells attenuated tumorigenesis 25 imply an oncogenic role of ERp29 in breast tumor formation. In contrast, Shnyder et al. 24 also observed a low level of ERp29 in proliferative and metastatic MDA-MB-435 cells compared with MCF-7 cells, and an inverse correlation between ERp29 expression and tumor progression, although not at a significant level. Furthermore, expression of ERp29 was higher in the slow-growing tumors formed by MCF-7 or COLO 205 cell lines than in the fast-growing tumors produced by MDA-MB-435 or SW-620 cell lines. These phenomena may indicate a potential function of ERp29 in negatively regulating cell proliferation and/or tumorigenesis. In view of these controversial findings, the pathophysiological role of ERp29 in breast cancer progression remains elusive and needs to be further assessed.
This study aims at examining the functional consequences of ERp29 in breast cancer cells. Our study shows that ectopic expression of ERp29 in MDA-MB-231 cells results in G 0 /G 1 arrest, causes mesenchymal-epithelial transition (MET) and suppresses tumor growth in nude mice. We show a tumor suppressive role of ERp29 by driving the molecular alterations in proliferative/invasive MDA-MB-231 cells. 
MATERIALS AND METHODS

Clinical Specimen and Cell Culture
In this study, 12 frozen breast tumor tissues and 12 adjacent nontumor breast tissues were obtained from the Tissue Repository of the Singapore National University Health System with informed patient consent. Usage of these tissues complied with the regulations set by our Institutional Review Board (IRB) for research purposes.
The MDA-MB-231, SKBr3, and MCF-7 human breast cancer cell lines were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA). Both MDA-MB-231 and MCF-7 cells were cultured in DMEM medium supplemented with 10% fetal bovine serum (FBS, Invitrogen) and were maintained at 37 1C with 5% CO 2 in a humidified incubator. SKBr3 cells were cultured in McCoy5A medium with 10% FBS. ERp29-transfected MDA-MB-231 and SKBr3 cells and shRNA/ERp29-transfected MCF-7 cells and their respective vector-transfected control cells were maintained in a medium supplemented with 10% FBS and G418 (2 mg/ml for MDA-MB-231 single clones, 0.5 mg/ml for SKBr3 mixed clones and 1 mg/ml for MCF-7 mixed clones).
Plasmids
The vector control plasmid, pcDNA3.1( þ ), was purchased from Invitrogen. The full-length cDNA of the human ERp29 gene was amplified by PCR and cloned into pcDNA3.1( þ ) to form expression vector pcDNA-ERp29. The authenticity of the ERp29 gene sequence was confirmed by DNA sequencing. A hairpin shRNA targeting ERp29 (NM_006817) and a control shRNA targeting EGFP cDNA were constructed and cloned into pSilencer2.0-U6 (Ambion, Austin, TX, USA), as described in the Supplementary Materials and Methods.
Transfection and Generation of Stable Clones
For single clone generation, MDA-MB-231 cells (2 Â 10 5 per well) seeded in 6-well plates were transfected with 1 mg of either pCDNA-ERp29 or pcDNA3.1 using LipofectAMINE (Invitrogen) according to the manufacturer's instructions. Transfectants were propagated in DMEM with G418 (2 mg/ ml) for 48 h and then subcultured in Petri dishes after serial dilution. Colonies produced from single cells were detached in cloning cylinders (Millipore Corporation) and transferred into a 96-well plate for cell propagation. Two ERp29-over- medium with G418 (0.5 mg/ml) or DMEM medium with G418 (1.0 mg/ml) and used in this study. Cells transfected with vector pcDNA 3.1 or pshCtrl were used as a control. Expression of ERp29 was verified by reverse transcription-polymerase chain reaction (RT-PCR) and western blotting.
Cell Proliferation and Cell Cycle
Cell proliferation and cell cycle analysis were performed as described earlier. 26 . Briefly, cells (1 Â 10 3 per well) were seeded in triplicate in 96-well culture plates and cultured for 4 days at 37 1C in a humidified, 5% CO 2 atmosphere. Viable cells were quantified at each 24-h interval using CellTiter 96 s; Aqueous One Solution Cell Proliferation Assay (Promega, Mannheim, Germany). The absorbance at 492 nm was measured using an Infinite F200 microplate reader (TECAN Austria GmbH, Grodig, Austria). For cell cycle analysis, serum-starved cells were collected, fixed with ice-cold 80% ethanol for 1 h at 4 1C and stained with 1-ml propidium iodide/RNAase staining buffer (BD Biosciences, San Diego, CA, USA) for 1 h in the dark, followed by flow cytometric analysis (FACSCalibur, Becton Dickinson, Mansfield, MA, USA). The fraction of cells in each cell cycle phase (G 0 /G 1 , S and G2/M) was determined from the DNA histograms using Cyan LX software.
Cell Migration
Cell migration was assessed using wound healing and Transwell assays. 26 For wound healing assay, monolayer cells at 90-95% confluence were serum starved for 24 h and then carefully wounded using sterilized pipette tips. After removing detached cells, the cells were incubated at 37 1C for 15 h. Wound cells were photographed immediately (t ¼ 0) and after being cultured for 15 h. Quantitative cell migration assays were performed using Cytoselect TM 24-Well Cell Migration Assay (Cell Biolabs, San Diego, CA, USA). Briefly, cells were serum starved for 24 h, harvested and seeded (7.5 Â 10 5 cells/ml) in triplicate into the upper chambers. The inserts were then put into wells containing 0.5 ml of medium with 10% FBS, and incubated at 37 1C for 20 h in a 5% CO 2 incubator. Upon removal of nonmigratory cells with cotton swabs, migratory cells were stained and quantified at 570 nm, according to the provided protocol.
Matrigel Invasion
In vitro cell invasion was measured using QCMt 24-Well Cell Invasion Assay (Chemicon International, Temecula, CA, USA) with an 8 mm pore size according to the manufacturer's instructions. Briefly, cells were serum starved for 24 h and harvested. Equal number of cells (7.5 Â 10 5 cells/ml) were seeded in triplicate onto the top of the Matrigel layer in the inserts and incubated at 37 1C for 24 h, with 10% FBS in the lower chamber. The cell suspension was aspirated and excess Matrigel was removed from the filter using cotton swabs. Cells at the bottom of the membrane were then dissociated with cell detachment buffer, and subsequently lysed and detected using CyQuant GR s dye. Relative cell invasion was determined on the basis of fluorescence reading at 485/ 535 nm.
Anchorage-Independent Growth in Soft Agar and Cell Transformation Colony-forming efficiency in soft agar was performed using the CytoSelectt 96-Well Cell Transformation assay (Cell Biolabs). Briefly, viable single cells (1 Â 10 4 ) in 0.3% agar solutions were plated in triplicate over a layer of medium with 0.5% agar in a 96-well plate and incubated for 2 weeks in a humidified incubator at 37 1C with 5% CO 2 . Colonies on the soft agar were photographed and transformed cells were lysed and detected using CyQuant Working Solution (Cell Biolabs) according to the manufacturer's protocol. Transformation efficiency was calculated according to the fluorescence reading at 485/535 nm.
Immunofluorescence and Confocal Microscopy
Immunofluorescence analysis was performed as described earlier. 26 Briefly, cells plated on coverslips were fixed with 4% paraformaldehyde (Sigma-Aldrich) for 20 min and permeabilized with 0.1% Triton X-100 for 10 min. The cells were then incubated overnight with primary antibodies against FN or E-cadherin or vimentin at 4 1C, followed by incubation with Alexa Fluor 488-conjugate streptavidin (1:2000, Invitrogen) for 1 h at room temperature. Actin filaments were stained with rhodamine-phalloidin (1:1000, Invitrogen) for 45 min. After the final washes with PBS, the coverslips were mounted using an antifade mounting fluid containing DAPI and images were examined and captured using an Olympus Fluoview FV500 confocal laser scanning microscope (Olympus, Japan). Raw images were analyzed using Olympus FV10-ASW 1.7 Viewer software (Olympus).
Western Blot Analysis
In all, 40 mg of protein was resolved by SDS-PAGE and transferred onto a PVDF membrane, and then probed with specific antibodies (ERp29, 1:2500; Akt, 1: 1000; p-Akt, 1:500; ERK, 1:1000; p-ERK, 1:500; E-cadherin, 1:200; and vimentin, 1:500). Goat-anti-mouse or goat-anti-rabbit IgG horseradish peroxidase (HRP, Upstate Biotechnology, Lake Placid, NY, USA) was used as secondary antibody. Chemiluminescent signals were visualized using SuperSignal West Pico Chemiluminescent Substrate (Pierce) and signal intensity was analyzed using GeneTools software (Syngene, Frederick, MD, USA). The level of b-actin was used as loading control. In all, 98 tumor and adjacent nontumor breast tissues were respectively arrayed on two paraffin blocks using a tissue-arraying instrument (Beecher Instruments, Silver Spring, MD, USA) at the Diagnostic Molecular Pathology Centre according to a similar procedure as described earlier. 27 Immunostaining of ERp29 was performed using the DAKO Envision þ system (Dako, Glostrup, Denmark). Briefly, both tumor and nontumor tissue sections were blocked with 3% hydrogen peroxide after antigen unmasking with DAKO s Target Retrieval Solution in a microwave oven. Sections were incubated for 1 h with anti-ERp29 (1:500), followed by detection with labeled dextran polymer conjugated with peroxidase and DAB þ -substrate chromogen solution. The staining level was scored as negative (0), weak (1), moderate (2) and strong (3), according to the staining intensity of tumor cells. Tumors with a strong staining intensity of ERp29 were considered as high expression, while the others were considered as low expression. All sections were examined without previous knowledge of clinical information for any of the cases.
Proliferation Index and Cell Apoptosis in Mice Tumors
Frozen tumor tissues from mice were processed for paraffin block preparation using embedding molds. Paraffin sections were cut at 4 mm thickness and stained by hematoxylin and eosin (H&E). Immunohistochemical staining for ERp29 or Ki67 was carried out using the Dako Envision þ system as described above. Slides were washed, counterstained with Mayer's hematoxylin and mounted. The staining intensity of ERp29 or Ki67 in tumor cells was assessed under light microscopy. Tumor cell apoptosis was assessed by evaluating TUNEL-positive cells using the DeadEnd Fluorometric TUNEL System (Promega, Madison, WI, USA). TUNEL staining was performed using TUNEL labeling mix according to the manufacturer's protocol (Supplementary Materials and Methods), and counterstained with DAPI. Fluorescence images were captured using an Olympus Fluoview FV500 confocal laser-scanning microscope (Olympus).
Real-Time PCR Array
Real-time PCR array analysis on the genes involved in the MAPK and PI3K/Akt pathway and cell invasion/metastasis was performed using the RT 2 Profilert PCR Array (SuperArray Bioscience Corporation, Frederick, MD, USA). Briefly, 0.5 mg of total RNA was used for first-strand cDNA synthesis using the RT 2 First Strand Kit according to the provided protocol. RT-PCR was carried out with the 96-well plate format and the ABI 7500 Fast Real-Time PCR System (Applied Biosystems, Singapore). Gene amplification was detected with SYBR, and data analysis was carried out using the DDCt method (http://www.superarray.com/pctarraydataanalysis.php) according to the manufacturer's instructions. Relative expressions of genes were expressed as fold changes compared with control. Unsupervised hierarchical clustering was performed after filtered data were log 2 transformed using GeneSpring GX10.0 software, and results were shown using the TreeView program (Agilent Technologies, Santa Clara, CA, USA).
Reverse Transcription (RT)-PCR
Total RNA from cells was extracted using NucleoSpin RNA II (Macherey-Nagel GmbH & Co. KG, Germany), and cDNA was synthesized using ImProm-II reverse transcriptase (Promega) according to manufacturer's protocol. The genes of ERp29, CDH1, CD82, EPHB2, CXCL12, ETV4, SYK, CCND2, CDKN2B, MAP4K1, uPAR and EGFR were amplified by semiquantitative PCR using their respective specific primers (Supplementary Materials and Methods). b-Actin was used as loading control.
Statistical Analysis
All cell culture experiments were carried out in triplicate and repeated at least twice. One-way analysis of variance or Student's t-test was used to analyze the significance of differences. Two-tailed Po0.05 was considered significant and data are presented as means±s.d.
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RESULTS
Erp29 is Downregulated in Breast Carcinoma
We analyzed the expression pattern of ERp29 in 12 pairs of breast cancer tissues by immunoblotting. As shown in Figure 1a , the level of ERp29 is highly reduced in tumors when compared with a group of matched nontumor counterparts, suggesting a suppressive role of ERp29 in tumorigenesis. In the tissue array study, ERp29 was immunohistochemically stained and the level of ERp29 was assessed according to staining intensity. After immunohistochemical staining, 54 nontumor tissues and 91 tumor tissues were available for scoring. Representative IHC sections showing high and low staining intensity of ERp29 in both nontumor and tumor specimens are shown in Supplementary Figure 1 . With these criteria, we found that ERp29 was highly stained in 75% of nontumor tissues (n ¼ 54) and in 45% of tumor tissues (n ¼ 91) (Po0.05) (Figure 1b) . We then investigated the correlation of ERp29 with the clinicopathological parameters of these tumors and found that ERp29 is highly expressed in a group of tumors with lower stage or lower grade or with lymph node negative when compared with tumors with more aggressive characteristics (Figure 1c ). However, we did not observe significant associations of ERp29 with HER-2/neu and ER status (data not shown). We thus show that ERp29 expression is progressively repressed during cancer progression.
Erp29 Negatively Regulates Cell Proliferation in Breast Cancer Cells
To characterize the possible association of ERp29 with cell proliferation and/or invasive capability, we analyzed ERp29 expression in a panel of breast cell lines, including nontumorigenic MCF-10A and MCF-12A cells, low-proliferative MCF-7 cells and high-proliferative MDA-MB-231, as well as SKBr3 and BT549 cells. As shown in Figure 2a , the level of ERp29 in high-proliferative cancer cells is highly reduced (Po0.05) when compared with that in MCF-7 cells, which has the weakest invasive potential 28 and dormant characteristics. Figure  3) . Taken together, the data indicate that ERp29 negatively regulates cell growth in breast cancer cells.
Erp29 Regulates Mesenchymal-Epithelial Transition in MDA-MB-231 Cells
We observed an important change of cell morphology induced by ERp29 in MDA-MB-231 cells. As shown in Figure 3a , mock-transfected control cells show a spindle-like fibroblastic morphology, whereas ERp29-transfected MDA-MB-231 cells (clone B and E) show a cobble-stone-like phenotype, which is identical to that observed in dormant MCF-7 cells. We also observed that ERp29-transfected MDA-MB-231 cells grew to form clusters, whereas mock-transfected control cells grew sparsely when cells were cultured in flasks (Supplementary Figure 4) . Phalloidin staining further verified a significant difference in the cell shape and distribution of F-actin, implying that ERp29-transfected MDA-MB-231 cells underwent cytoskeletal reorganization with loss of filamentous stress fibers and cortical actin formation (Figure 3b) . Concomitantly, the extracellular matrix (ECM) component FN, which is involved in cell transition from quiescence to proliferation, 29 was decreased in ERp29-transfected MDA-MB-231 cells, as shown by immunofluorescent staining (Figure 3c ). Importantly, we observed that epithelial cell marker E-cadherin was highly expressed in both clone B and E cells and its membranous distribution is identical to that observed in MCF-7 cells (Figure 3d) . Meanwhile, the mesenchymal cell marker vimentin was highly reduced in both clone B and E (Figure 3e ). RT-PCR and immunoblotting analyses further showed the transcriptional reactivation of E-cadherin by ERp29 (Figure 3f) . We also examined the expression of Twist, a transcription factor that negatively regulated E-cadherin expression during epithelial-mesenchymal transition (EMT), 30 and verified its reduced expression in both the ERp29-transfected clones (Figure 3f, right panel) . In addition, when ERp29 was silenced in MCF-7 cells, the level of vimentin was increased, whereas the level of E-cadherin was decreased, as assessed by immunofluorescent staining (Supplementary Figure 5) , further showing that downregulation of ERp29 promotes EMT. In short, with the loss of mesenchymal cell marker vimentin and reactivation of E-cadherin in ERp29-transfected MDA-MB-231 cells, we conclude that ERp29 negatively regulates the EMT process in breast cancer cells.
Overexpression of Erp29 Reduces Cell Motility, Invasion, and Transformation
Epithelial-mesenchymal transition is a central process implicated in cancer invasion and metastasis. 31, 32 ERp29-mediated MET may negatively regulate cell migration and invasion. In line with this notion, we found that the wound healing abilities of ERp29-transfected MDA-MB-231 cells (clone B and E) are markedly repressed, compared with those observed in mock-transfected control cells (Figure 4a ). In contrast, knockdown of ERp29 in MCF-7 cells increased wound healing capacity. Quantitative analysis using Transwell chamber further showed the reduced cell motility of ERp29-transfected MDA-MB-231 (Po0.01) and the increased migration of ERp29-silenced MCF-7 cells (Po0.05, Figure 4b ). In addition, ERp29 significantly decreased the invasive capacity of MDA-MB-231 cells (Po0.05), although knockdown of ERp29 by shRNA in MCF-7 cells improved cell invasive capacity (Po0.05, Figure 4c ). Similar results were also observed in ERp29-transfected SKBr3 cells, in which overexpression of ERp29 reduced cell migration and invasion (Supplementary Figure 6a, b) . As such, these results show that ERp29 negatively modulates cell migration and invasion in breast cancer cells.
Given that the colony-forming capacity of mammalian cells in soft agar correlates with their tumorigenic potential, Figure 6c) .
Erp29 Suppresses Tumor Formation In Vivo
We then investigated the effect of ERp29 on tumor growth in a xenograft model. We observed that all the mice injected with control cells showed visible tumors within 21 days after inoculation (mean ¼ 30.8 mm (Figure 6c ). TUNEL staining indicated that no significant difference of apoptotic cells was found in tumors developed from ERp29-transfected cells as compared with that from control tumor cells (Figure 6d ). These results suggest that the reduction in the cell proliferation rate of ERp29-transfected MDA-MB-231 cells is responsible for tumor suppression in vivo.
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Identification of Erp29-Regulated Genes Involved in Cell Proliferation and Invasion
Our investigation reveals that overexpression of ERp29 in MDA-MB-231 cells results in MET and in reduction of cell proliferation/invasion and tumorigenesis. Given that MAPK/ ERK and PI3K/Akt signaling pathways have been hyperactivated in EMT, 33, 34 we examined whether these two cascades were negatively regulated by ERp29 during ERp29-mediated MET. To this end, we performed RT-PCR array-based gene expression profiling by targeting MAPK and PI3K/Akt signaling pathways, as well as the genes involved in tumor invasion/metastasis. In all, 125 of 252 genes were differentially transcribed (by42.0 fold) in both ERp29-transfected clone B and E cells. Of them, 59 were upregulated, whereas 66 were downregulated (Supplementary Table 1 ). The unsupervised clustering of these genes was shown in Supplementary Figure 7 and the genes showing at least 10-fold difference are indicated in Figure 7a . We found that ERp29 could activate the transcription of a group of genes involved in tumor suppression (eg, SYK, CDH1, etc) and cell (Figure 2 ). In the MAPK cascade, MAP4K1, MAP2K6, MAPK81P2, MAPK3 and MAPK10 were transcriptionally upregulated, whereas MAPK12/13/14, MAPK8 and MAP2K3 were downregulated. Several important transcriptional factors (eg, Ets-1 and E2F) were also transcriptionally repressed by ERp29. Meanwhile, transcription of the regulatory subunit of PI3K (PI3KR1 and PI3KR2) and Akt1 was increased, whereas transcription of the catalytic subunit of PI3K (P3KCG) and Akt3 was reduced by ERp29 (Supplementary Table 1 ). RT-PCR further verified the differential expression of upregulated (SYK, CDKN2B, MAP4K1 and CXCL12) and downregulated genes (CCND2, UPAR, EGFR, EPHB2, CD82 and ETV4) in ERp29-transfected MDA-MB-231 cells (Figure 7b ). 
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In addition to the transcriptional activation/inhibition of genes regulating invasion/metastasis and MAPK and PI3K cascades, overexpression of ERp29 in MDA-MB-231 cells significantly increased both expression and phosphorylation of ERK1 (MAPK3), and highly inhibited the phosphorylation of ERK2 (MAPK1), whereas the overall phosphorylation of p-ERK1/2 was reduced in ERp29-transfected clone B and E cells (Figure 7c ). When ERp29 was silenced in MCF-7 cells, both ERK1 and two were highly phosphorylated, whereas the basal level of ERK1/2 was not changed (Figure 7c) . Interestingly, we also found that ERp29 differentially regulated the phosphorylation of ERK1 and ERK2. The ratio of p-ERK1 to p-ERK2 was highly increased in ERp29-transfected clone B and E cells and was highly decreased in ERp29-silenced MCF-7 cells. These results indicated that ERp29 may regulate MAPK signaling by tuning the ratio of p-ERK1 to p-ERK2. However, phophorylation of Akt was only slightly increased, indicating a less effectiveness of ERp29 in regulating the overall activation of the PI3K/Akt cascade (Figure 7c ). In general, our results show that ERp29 is a central molecule in modulating signal pathways at both transcriptional and translational levels.
DISCUSSION
Recent studies have established the key roles of major reticuloplasmins, including Bip/GRP78, PDI and other ER stress molecules (eg, PERK and p-eIF2a) in cancer cell apoptosis, survival and tumorigenesis. 15, [35] [36] [37] In this study, we show that ERp29 is a novel regulator in modulating cell growth arrest and phenotypic changes associated with MET in proliferative/invasive breast cancer cells. Importantly, we show that ERp29 is a potential tumor suppressor in breast cancer progression.
We reported here that ERp29 exerts a growth-inhibitory effect in breast cancer cells. This was supported by our findings that overexpression of ERp29 in the proliferative MDA-MB-231 cells and SKBr3 cells significantly attenuated cell growth, whereas silencing ERp29 in low proliferative MCF-7 cells enhanced cell growth. We observed that the reduced cell proliferation in proliferative MDA-MB-231 cells was caused by the ERp29-mediated cell cycle arrest at the G 0 / G 1 phase (Figure 2 ). In keeping with this, we found that key cell cyclins at the G 0 /G 1 phase, for example, CCND1, CCND2 and CCND3, were highly downregulated, whereas inhibitor CDKN2B was significantly upregulated in ERp29-transfected MBA-MD-231 cells, as assessed by RT-PCR-array (Figure 7b , Supplementary Table 1 ). Considering that ER stress signaling PERK/p-eIF2a has an essential role in regulating G 0 /G 1 arrest by deregulating cyclin D1/D2, 13 it is meaningful to investigate the mechanism by which ERp29 regulates ER stress signaling and thereby cell cycle arrest.
A novel finding of our study is that ERp29 regulates cytoskeleton reorganization and MET transition in MDA-MB-231 cells ( Figure 3 ). As the cell shape and cytoskeletal configuration have a critical role in regulating the transition of cells from a nonproliferative to a proliferative state, 4, 29, 38 the ERp29-mediated cytoskeletal reorganization in proliferative MDA-MB-231 cells indicated ERp29 as a novel regulator in inducing cell dormancy. This is further supported by the identical phenotype between ERp29-transfected MDA-MB-231 cells and dormant MCF-7 cells. Repression of a cell proliferation regulator FN 29 in ERp29-transfected MDA-MB-231 cells further supports the role of ERp29 in driving proliferative cells into a quiescent state. Accompanying the phenotypic change, we showed that E-cadherin, a key component of adherens junctions with a crucial role in the maintenance of epithelial integrity, 39 was transcriptionally activated and highly expressed in ERp29-transfected MDA-MB-231 cells by downregulating the transcriptional factor twist (Figure 3f ). Given that E-cadherin expression inhibited the EMT process, 40 reactivation of E-cadherin and loss of mesenchymal cell marker vimentin in ERp29-transfected MDA-MB-231 cells suggest that these transfected cells undergo MET. Although the basis of ERp29-mediated MET transition in proliferative/invasive breast cancer cells remains elusive, we report, for the first time, that ERp29 is a novel regulator in modulating MET in invasive breast cancer cells.
This study shows ERp29 as a novel tumor suppressive factor in breast cancer. Increased expression of ERp29 inhibited cell migration, invasion and transformation in vitro in ERp29-transfected MDA-MB-231 and SKBr3 cells and vice versa in ERp29-silenced MCF-7 cells. Importantly, we confirmed that expression of ERp29 in proliferative MDA-MB-231 cells significantly delayed tumor initiation and dramatically inhibited tumor growth in a nude mice xenograft model, with a decreased cell proliferative index. The observed in vivo tumor suppression is consistent with our results with clinical samples: ERp29 is downregulated in tumors when compared with nontumor tissues and progressively reduced with tumor progression. In support of our findings, studies from Shnyder et al. 24 showed that cells (MCF-7 and COLO205) with a high level of ERp29 produced slow-growing tumors, whereas cells (MDA-MB-435) with a low level of ERp29 developed fast-growing tumors. Nevertheless, conflicting results have been reported by Mkrtchian et al. 25 They found that mutant ERp29C157A inhibited tumor growth as compared with wild-type ERp29, and the size of established tumors could not be further increased when tumors were treated with ERp29 siRNA. Although the reasons of this discrepancy are uncertain, one possible explanation may be that tumor suppression by nonfunctional mutant ERp29C157A is apparently because of the disruption of a secretion pathway, 41 which may affect stromal-tumor cell interaction. There is no further evidence to show that mutation of C157A could result in molecular alterations, which exert tumor suppressive capacity. In contrast, our in vitro and in vivo studies, together with the observations in the clinical specimen, established the tumor suppressive function of ERp29 in breast cancer.
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The mechanisms by which ERp29 suppresses tumor growth are not fully understood; however, ERp29-mediated cell growth arrest, not cell apoptosis, and ERp29-driven MET transition, which enables cells to lose their invasive and metastatic properties, 31 may provide an insight into this process. In addition, the gene expression profiling analysis revealed a complexity of differentially expressed genes that may be involved in the tumor suppressive effect of ERp29 in breast cancer cells. For example, tumor suppressor genes (eg, CDH1 and SYK) were transcriptionally activated and highly expressed, whereas the genes regulating cell proliferation (eg, uPAR, FN and EGFR) were significantly reduced in ERp29-transfected MDA-MB-231 cells (Supplementary Table  1 , Figure 7 ). E-cadherin suppressed tumor formation by preventing genomic instability, 42 whereas SYK negatively regulated cell proliferation, invasion and tumor formation. 43 EGFR and uPAR were found to positively regulate cell migration, invasion and tumorigenesis. 44, 45 Furthermore, the genes involved in MAPK and PI3K pathways are transcriptionally regulated and the overall activation of ERK cascade is inhibited by ERp29. The reduced ERK1/2 cascade in ERp29-transfected MDA-MB-231 cells further supports the involvement of ERK cascade in regulating EMT. 34, 46 In addition to the overall reduction of p-ERK1/2, p-ERK1 and p-ERK2 were differentially regulated, whereby p-ERK1 was enhanced and p-ERK2 was attenuated in ERp29-transfected MDA-MB-231 cells (Figure 7c ). Given that ERK1, which could antagonize ERK2 signaling, negatively modulates colony formation and tumorigenesis in nude mice, 47 the ERp29-enhanced ratio of p-ERK1/p-ERK2 may imply a novel regulatory model in determining ERp29-mediated ERK signaling activity and in driving their apparent biological differences.
In summary, we show that ERp29 negatively regulates cell growth by causing G 0 /G 1 arrest. Importantly, we report a novel function of ERp29 in modulating MET transition by transcriptional activation of E-cadherin and in suppressing tumorigenesis through a complexity of molecular alterations. These findings provide a novel insight into the involvement of ERp29 in breast cancer progression. Future studies will examine ERp29-regulated genome-wide downstream signals to elucidate the molecular mechanisms underlying the phenotypic and pathological characteristics, and to investigate its involvement in metastasis using in vivo animal models.
